Tofacitinib citrate 99.8%

Tofacitinib citrate Info

Tofacitinib citrate is an oral small molecule Janus kinase (JAK) inhibitor, primarily used for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). It works by selectively inhibiting the activity of Janus kinases, thereby blocking cytokine signaling pathways and reducing the activity of inflammatory cells, which helps to alleviate the symptoms and progression of RA.

What is Tofacitinib Citrate?

Tofacitinib citrate,  is a JAK inhibitor that targets JAK3, JAK2, and JAK1 with IC50 values of 1 nM, 20 nM, and 112 nM, respectively . It is an oral medication that has been developed by Pfizer and has been approved by the FDA for use in certain conditions since 2012 .

Uses of Tofacitinib Citrate

Tofacitinib citrate has several approved uses:

Rheumatoid Arthritis (RA): It is used for the treatment of moderate to severe active RA in adults who have not responded well to methotrexate or other non-biological DMARDs

Psoriatic Arthritis: It is also used for the treatment of psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitors .

Ankylosing Spondylitis: Tofacitinib citrate is prescribed for the treatment of active ankylosing spondylitis in adults .

Ulcerative Colitis: It is used for the treatment of moderately to severely active ulcerative colitis in individuals who have had an inadequate response or intolerance to TNF inhibitors .

Polyarticular Juvenile Idiopathic Arthritis: In patients who have had an inadequate response or intolerance to one or more TNF inhibitors .

Investigational Use: It is also being investigated for the treatment of coronavirus disease 2019 (COVID-19) in certain hospitalized patients .

Summary

In summary, tofacitinib citrate is a JAK inhibitor with a broad application in the treatment of various inflammatory conditions, including RA, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Its mechanism of action involves the inhibition of JAK enzymes, which are key players in the cytokine signaling pathways that contribute to inflammation. As a therapeutic option, tofacitinib citrate offers an alternative for patients who do not respond well to traditional DMARDs or biologic agents. It is important to note that the use of tofacitinib citrate requires careful consideration of potential drug interactions and patient-specific factors, and it should be administered under the guidance of a healthcare professional.